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ell therapy is an exciting option for repairing the injured heart, one that has attracted considerable interest over the past 15 years. Consensus exists that the injection/infusion or tissue-based implantation of various cell types may exert therapeutic effects, [1] [2] [3] and there is general agreement that additional molecular, translational, and clinical studies are required to define the optimal cell source, method of delivery, and underlying mechanism(s) of action.
One of the remaining questions in this field pertains to cardiomyocyte turnover under normal and diseased conditions and its contribution to the beneficial effects of cell therapy. Although results published in the literature have not been consistent, we believe that the time is ripe to formulate a consensus for many of the pertinent questions.
It is important to emphasize that the focus of this consensus statement is on cardiomyocyte renewal; it is not on cell therapy in general. Although we touch on some aspects of therapeutic strategies based on delivery of exogenous cells, our intent here is to define areas of agreement and areas requiring further elucidation related to the regenerative potential of the myocardium itself.
We have included references to the scientific literature throughout the document. Although it is impossible for us to include all publications in this expansive field, representative studies that corroborate statements herein have been cited.
CENTRAL QUESTIONS
1. Definition of cardiomyocyte renewal. In this consensus statement, the term cardiomyocyte renewal is defined as the ability to replace lost cardiomyocytes by new ones. It is distinct from the turnover of cardiac proteins or the generation of polyploid cardiomyocytes (ie, those harboring >2 sets of chromosomes), either by nuclear division giving rise to multinucleation or by duplication of DNA without nuclear division resulting in polyploid nuclei.
2. Naturally occurring cardiomyocyte renewal and proliferation. A. During normal mammalian development i. Growth of the heart during embryonic and fetal development involves an absolute increase in the number of cardiomyocytes and is brought about by differentiation of precursor cells and by division of relatively immature cardiomyocytes. ii. The rodent heart continues to grow by means of cardiomyocyte proliferation (hyperplastic growth) in the early postnatal period. 4 During a brief postnatal window of 7 days in rodents, myocardial injury induces a regenerative response, resulting in replacement of lost cardiomyocytes by new ones. 5 Fate-mapping studies suggest that this type of myocardial regeneration is mediated primarily by cardiomyocyte proliferation. 5 It remains unclear whether this regenerative window exists in large animals or in humans. iii. Although cardiomyocytes appear to continue to renew throughout life, the quantitatively dominant mechanism of growth in the mammalian postnatal heart is an increase in cardiomyocyte size (reviewed by Heineke and Molkentin 6 ). iv. In the healthy, uninjured adult human and murine heart, the total number of cardiomyocytes remains essentially stable, and cardiomyocyte turnover is currently estimated at 0.5% to 2% per year in both species. 4, [7] [8] [9] B. After cardiac injury in adult mammals i. Cardiomyocyte renewal rates may be higher after injury than under normal conditions. ii. The experimental determination of cardiomyocyte turnover after cardiac injury can be challenging owing to inflammation, proliferation of stromal and vascular cells, and scar formation. C. After heart or bone marrow transplantation (chimerism) i. Sex-mismatched heart transplantation in patients with end-stage heart failure or sexmismatched bone marrow transplantation provides opportunities to ascertain experimentally cardiomyocyte renewal deriving from extracardiac sources. ii. Although data are not completely consistent, the preponderance of studies suggest that the level of cardiomyocyte chimerism after sex-mismatched transplantation is <1% [10] [11] [12] and may arise at least partially from fusion events. 10 iii. Insufficient data are available to determine the time course within which such chimerism develops. 3. Mechanisms of endogenous cardiomyocyte renewal. There is no infallible means of tracking cell renewal in any organ system. However, in preclinical models of cardiomyocyte renewal (eg, mouse and fish), genetic fate-mapping studies provide the strongest level of scientific evidence. Critical biological issues such as promoter fidelity (leakiness and sensitivity), inefficient reporter expression (Cre recombinase activity), and cellular fusion or transfer of reporter proteins are relevant and must be considered in the interpretation of the findings. Furthermore, appropriate control studies are essential to assess for deleterious consequences of haploinsufficiency that could result from genetic manipulation of an endogenous gene locus.
A. Cardiomyocyte proliferation i. The majority of studies suggest that cardiomyocyte renewal in the uninjured adult heart derives from a modest level of preexisting cardiomyocyte mitosis. [13] [14] [15] Support for this interpretation derives from experiments in zebrafish, 16, 17 newts, 18 and other species 19 in which cardiomyocyte renewal occurs more robustly than in mammals. B. Resident stem/progenitor cells i. Resident stem/progenitor cells contribute to multiple cell types within the ventricle, including cardiomyocytes. However, in terms of adult myocardial homeostasis in mice, current evidence suggests that their contribution under basal conditions or after cardiac injury is low (estimates in rodents based on genetic fate-mapping experiments suggest a rate of <0.01% per year). 20, 21 C. Extracardiac stem/progenitor cells i. The contribution of extracardiac stem or progenitor cells to cardiomyocyte renewal has been studied largely with chimeric mice, in which the bone marrow is genetically labeled, and in parabiotic mice, in which the circulation of a genetically labeled mouse is experimentally linked to another unlabeled mouse. Cell fusion and transdifferentiation events have been evaluated with genetic lineage tracing, and the findings are largely concordant. In humans, the role of extracardiac stem/progenitor cells in cardiomyocyte renewal has been studied by sex-mismatched heart and bone marrow transplantation. ii. Homing of extracardiac bone marrowderived cells to the uninjured heart is a rare event of uncertain physiological relevance. iii. Extracardiac bone marrow-derived cells enter the injured heart at a higher rate. The majority of these cells are of hematopoietic origin. iv. A small fraction of cardiomyocytes within injured rodent hearts carry the genetically determined label of bone marrow cells (estimates in rodents based on genetic fate-mapping experiments suggest a rate of <0.2% 22, 23 ). Most studies suggest that the majority of these cells originate from cell fusion and <1% derive from transdifferentiation (estimates in rodents based on genetic fate-mapping experiments suggest a rate of <0.002% in total 23 ). 4 ii. Fractionated bone marrow populations consisting of c-kit + cells or mesenchymal stem cells may confer structural or functional benefits primarily by indirect biological activities that may promote cardiomyocyte renewal. [34] [35] [36] iii. Initial studies with bone marrow-derived mesenchymal cells are promising, 37 and phase 3 trials are underway. iv. Evidence for the ultimate fate of mesenchymal cells after infusion or injection into the heart is inconsistent, but some studies report that unmanipulated mesenchymal cells can transdifferentiate into cardiomyocytes at low rates. [47] [48] [49] [50] [51] iii. Undifferentiated pluripotent stem cells can form teratomas when injected into the heart of immunocompromised organisms. 52 iv. Pluripotent stem cell-derived cardiomyocytes successfully engraft, generating new myocardium when injected into the injured or uninjured heart of immunosuppressed animals. [53] [54] [55] [56] [57] [58] * Long-term engraftment (>3 months) of these cells has not been studied. v. Pluripotent stem cell-derived cardiomyocytes can couple electrically with host cardiomyocytes, beating in synchrony, although evidence for proarrhythmic effects has been reported. 54, 58 vi. Although direct force generation deriving from the injected myocytes may explain some of the functional improvement, it is not clear whether the degree of emergence of new myocardium entirely accounts for the degree of contractile improvement; paracrine signaling events may contribute as well. D. Stimulation of endogenous cardiomyocyte proliferation † i. The normal turnover of cardiomyocytes can be stimulated as a therapeutic strategy to achieve regeneration. ii. Endogenous cardiomyocyte proliferation can be enhanced by manipulation of cell cycle regulators, 59, 60 by redox regulators, [61] [62] [63] by growth factors acting through cell surface receptors, 30, 64 or through the transfer of nucleic acids acting intracellularly. 17, 65, 66 5. Important questions remaining to be answered A. Identify mechanisms of endogenous cardiomyocyte renewal in mammals as a target for therapy, including mechanisms of cardiomyocyte proliferation and characterization of populations of proliferative cardiomyocytes. B. Define the relative roles of progenitor cell differentiation versus cardiomyocyte proliferation in regenerating the injured myocardium. C. Unveil mechanism(s) of benefit deriving from cell-based therapy, including the contribution of new cardiomyocytes, angiogenesis, antiinflammatory actions, antifibrotic actions, antiapoptotic actions, or other effects. D. Define the paracrine mechanisms or host immune response signals that mediate many of the beneficial effects of cell therapy. E. Improve the efficiency of cell therapy with regard to modes of delivery, enhancement of engraftment, and differentiation. F. Explore new therapeutic options that provide the same beneficial effects as cellular transplantation through exosomes, selected paracrine factors, or induction of the innate and adaptive sterile immune responses in the heart. G. Define the risk/benefit aspects for genetically modified stem cells, pluripotent stem cell-based therapies, and cell combination strategies. 
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